Qudexy Xr

Migraine, Caloric Restriction, High cholesterol + 16 more

Treatment

20 Active Studies for Qudexy Xr

Treatment for

Migraine

What is Qudexy Xr

TopiramateThe Generic name of this drug

Treatment SummaryTopiramate is a medication used to control epilepsy and prevent migraine headaches. It was first approved by the FDA in 1996 and later approved for migraine prevention in adults in 2004. It is also used in combination with another drug, phentermine, to help adults lose weight. It has an unusual chemical structure composed of sulfamate and oxygen, which was discovered by chance during the development of an antidiabetic medication.

Topamaxis the brand name

image of different drug pills on a surface

Qudexy Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Topamax

Topiramate

1997

526

Effectiveness

How Qudexy Xr Affects PatientsTopiramate helps to prevent seizures and migraine symptoms by decreasing the activity of neurons in the brain. However, it can also cause metabolic acidosis, changes in mood, suicidal thoughts or attempts, and kidney stones. Taking topiramate with another drug called valproic acid can also lead to hypothermia.

How Qudexy Xr works in the bodySeizures are caused by an electrical disruption in the brain, which causes a temporary disruption of normal brain activity. Topiramate is used to treat these seizures and migraines, although the exact way it works is not fully understood. It likely works by blocking sodium channels in the brain and increasing activity of inhibitory GABA-A receptors while reducing activity of stimulating glutamate receptors. This decreases the electrical signals in the brain, preventing seizures and migraines. Topiramate also blocks some carbonic anhydrase isozymes, but it is unclear what impact this has.

When to interrupt dosage

The recommended dosage of Qudexy Xr is contingent upon the diagnosed condition, including Seizures, Weight Reduction and Tonic - clonic seizures. The quantity of dosage fluctuates as per the procedure of delivery (e.g. Tablet, coated or Tablet) specified in the table underneath.

Condition

Dosage

Administration

Alcoholism

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

High cholesterol

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

at least one weight-related comorbid condition

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

prophylaxis of migraine headaches

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Type 2 Diabetes

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Hypertensive disease

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Caloric Restriction

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Weight Reduction

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Lennox Gastaut Syndrome (LGS)

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

increase in physical activity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Obesity

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Chronic Weight Management therapy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Exercise

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

BMI >27 kg/m2

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Weight

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Seizures

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Epilepsy

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Mood Disorders

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Migraine

, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Warnings

Qudexy Xr Contraindications

Condition

Risk Level

Notes

Metabolic Acidosis

Do Not Combine

There are 20 known major drug interactions with Qudexy Xr.

Common Qudexy Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Topiramate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Topiramate.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be increased when combined with Topiramate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Topiramate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Topiramate.

Qudexy Xr Toxicity & Overdose RiskThe toxic dose of topiramate in rats is above 1500 mg/kg. People who overdose on topiramate may experience symptoms such as low blood pressure, extreme acidity in the body, coma, stomach pain, vision problems, seizures, drowsiness, trouble speaking, confusion, dizziness, agitation, and depression. If the overdose is recent, doctors may suggest vomiting or pumping the stomach, as well as providing supportive care with activated charcoal and hemodialysis.

Qudexy Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Qudexy Xr?

313 active clinical trials are currently being conducted to assess the potential of Qudexy Xr to ameliorate Type 2 Diabetes, Migraine and Exercise-related issues.

Condition

Clinical Trials

Trial Phases

prophylaxis of migraine headaches

0 Actively Recruiting

Weight

0 Actively Recruiting

Migraine

52 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Hypertensive disease

19 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

High cholesterol

5 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Type 2 Diabetes

192 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 1, Phase 4, Phase 3

Seizures

2 Actively Recruiting

Phase 3

increase in physical activity

0 Actively Recruiting

Caloric Restriction

0 Actively Recruiting

Chronic Weight Management therapy

0 Actively Recruiting

BMI >27 kg/m2

0 Actively Recruiting

Weight Reduction

1 Actively Recruiting

Not Applicable

at least one weight-related comorbid condition

0 Actively Recruiting

Epilepsy

0 Actively Recruiting

Obesity

0 Actively Recruiting

Alcoholism

7 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Mood Disorders

1 Actively Recruiting

Not Applicable

Lennox Gastaut Syndrome (LGS)

3 Actively Recruiting

Phase 2, Phase 3

Exercise

54 Actively Recruiting

Phase 1, Not Applicable, Phase 2, Phase 3

Qudexy Xr Reviews: What are patients saying about Qudexy Xr?

5Patient Review

9/11/2017

Qudexy Xr for Migraine Prevention

I use this because I have basilar migraines and i was on 100 mg of topomax xr but it stopped working for me so my neurologist bumped me up to 150mg to quedexy and it works great for me i have had no probelms! when i was taking the topomax I had tingling in my fingers and toes and knees and I also had nightmares for a month everytime I closed my eyes, but with quedexy I have never felt better!

2.7Patient Review

10/17/2016

Qudexy Xr for Migraine Prevention

I was previously taking topamax 100mg, but my doctor switched me to Qudexy at my annual visit. I found that I wasn't in a fog anymore, which was great! However, I experienced terrible stomach issues and bad tingling in my arms and legs. I tried staying with the medication for 3 weeks, but the stomach problems were too much to handle. I'm currently trying Trokendi to see if it will be more effective.

2Patient Review

1/14/2021

Qudexy Xr for Migraine Prevention

Although this medication did help to lessen my migraines by half, the hair loss after just three months was not worth it. Additionally, I frequently felt tingling in my fingers and toes while taking this drug.

1.7Patient Review

7/15/2016

Qudexy Xr for Migraine Prevention

I experienced a lot of negative side effects, like nausea and suicidal thoughts. This medication was ineffective for me, so I do not recommend it to others who are looking for relief from migraines.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qudexy xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Qudexy XR?

"The following effects may occur: fatigue, drowsiness, dizziness, loss of coordination, tingling in the extremities, loss of appetite, changes in food taste, diarrhea, and weight loss."

Answered by AI

What is Qudexy XR used for?

"Qudexy XR is a prescription medicine that can be used to prevent migraine headaches in adults and adolescents 12 years and older, and to treat certain types of seizures (partial-onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older."

Answered by AI

Is Qudexy the same as topiramate?

"The active ingredient in both Topiramate Extended-Release Capsules and Qudexy® XR is topiramate. Topiramate Extended-Release Capsules are manufactured by Upsher-Smith, while Qudexy® XR is manufactured by UCB, Inc."

Answered by AI

Is Qudexy XR used for weight loss?

"No, you should not use Qudexy XR for weight loss. Although weight loss is a potential side effect of the medication, the main purpose of Qudexy XR is to help people with epilepsy or those who suffer from migraines."

Answered by AI

Clinical Trials for Qudexy Xr

Image of University of Missouri - Kansas City School of Medicine in Kansas City, United States.

Behavioral Intervention for Type 2 Diabetes

Kansas City, MO

This trial is testing a program that combines diabetes coaching, financial rewards, and continuous glucose monitoring to see if it can help adults with type 2 diabetes better manage their condition. The study aims to determine

Waitlist Available

University of Missouri - Kansas City School of MedicineJared Bruce, PhD

Image of Behavioural Medicine Lab in Victoria, Canada.

Supernatural for Mental Health

Victoria, Canada

This trial aims to see if using virtual reality exercise can help improve mental health by looking at mood, well-being, and cognitive function over a 10-week period. It also wants to see if virtual

Behavioural Medicine LabRyan Rhodes, PhD

Image of Greenville VA Health Care Center in Greenville, United States.

Medically Reproduced Bariatric Surgery (MRB) for Obesity

"This trial aims to find a way to achieve the positive effects of gastric bypass surgery on weight loss and blood sugar control without actually undergoing surgery. The researchers believe that a combination of a medically supervised diet program

Waitlist Available

Greenville VA Health Care CenterMoahad Dar, MDSociété des Produits Nestlé (SPN)

Image of Honor Health Research Institute in Scottsdale, United States.

LY3209590 for Type 2 Diabetes

This trial aims to see how a drug called LY3209590 is absorbed and removed from the body in children with Type 2 Diabetes. The study will take around 100 days to complete.

Waitlist Available

Honor Health Research Institute (+5 Sites)Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company

Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.

Explore trials for Qudexy Xr

Image of University of Toronto, Mental Health and Physical Activity Research Centre in Toronto, Canada.

Physical Activity Intervention for Physical Activity

Toronto, Canada

"This trial aims to test the effectiveness of two different physical activity interventions (one-on-one and group-based) compared to a wait-list control group in supporting the mental health of post-secondary students. The study

University of Toronto, Mental Health and Physical Activity Research Centre

Image of Rowan University in Glassboro, United States.

Project WHADE: A Partner-Based Physical Activity Program for Women

This trial aims to test a new way of encouraging physical activity in women aged 40-65 with heart disease risk factors. Each participant gets a physical activity coach and a partner to support each other in

Rowan UniversityDanielle Arigo, Ph.D.

Image of Northwestern University Feinberg School of Medicine in Chicago, United States.

FoodSteps for Type 2 Diabetes

This trial aims to test a new mobile app that helps people with binge eating, diabetes, and food insecurity. The goal is to see if the app is easy to use, well-liked, and

Northwestern University Feinberg School of Medicine

Image of Arizona State University in Phoenix, United States.

Smart Walk for Heart Disease

This trial aims to test a smartphone app that is customized for African American women to help them be more active and lower their risk of heart disease and type 2 diabetes.

Arizona State University

Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.

Explore trials for Qudexy Xr

Image of Accellacare of Charleston in Mount Pleasant, United States.

Lu AG09222 for Migraine

Mount Pleasant, SC

This trial aims to find the right doses of Lu AG09222 to prevent migraines in people who have tried other medications without success.

Accellacare of CharlestonH. Lundbeck A/S

Image of National Research Institute_Huntington Park in Huntington Park, United States.

Semaglutide +1 More for Type 2 Diabetes

Huntington Park, CA

This trial will investigate whether a new experimental medicine called CagriSema can help people with type 2 diabetes reduce their blood sugar and body weight. Participants will be randomly assigned to receive either C

National Research Institute_Huntington Park (+11 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S

Image of Valley Clinical Trials, Inc. in Northridge, United States.

Cagrilintide for Type 2 Diabetes

"This trial will test a new medicine called CagriSema in people with type 2 diabetes to see if it can help lower their blood sugar and body weight. Participants will either receive Cag

Valley Clinical Trials, Inc. (+13 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S

Image of NYU Langone Health in New York, United States.

Video-Based Diabetes Self-Management Education and Support (DSMES) for Type 2 Diabetes

This trial aims to see if using video-based education and support for diabetes self-management, either alone or with a community health worker, is more effective than usual care in helping Chinese immigrants in NYC better control

Waitlist Available

NYU Langone HealthLu Hu, PhD

Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.

Explore trials for Qudexy Xr

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security